Incidence and management of infusion reactions to infliximab in 186 italian patient's with rheumatoid arthritis: The Padua experience;Frequenza e trattamento delle reazioni all'infusione di infliximab in 186 pazienti con artrite reumatoide: Esperienza di Padova

Reumatismo

Volumn 57, Issue 1, 2005, Pages 44-51

  Botsios, Costantino ^a,b   Ostuni, P ^a   Todesco, S ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Infliximab; Infusion reactions; Rheumatoid arthritis

Indexed keywords

CHLORPHENIRAMINE; CLONIDINE; DIAZEPAM; HYDROCORTISONE; IMMUNOGLOBULIN G1 ANTIBODY; INFLIXIMAB; KETOPROFEN; METHOTREXATE; METHYLPREDNISOLONE; PARACETAMOL; SALBUTAMOL; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; BRONCHOSPASM; DYSPNEA; FEMALE; FEVER; FLUSHING; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; ITALY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRURITUS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; THORAX PAIN; URTICARIA;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; INCIDENCE; INFUSIONS, INTRAVENOUS; ITALY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 15944424636     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Lipsky PE, van der Heijde D, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-602.
2. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomised controlled trial. Ann Int Med; 1999; 130: 478-86.
3. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
4. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 614-24.
5. Van den Bosch F, Kruithof E, Baeten D, Herssens A, De Keyser F, Mielants H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 2002; 46: 755-65.
6. Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48: 3230-6.
7. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50: 2264-72.
8. Antoni C, Manger B. Infliximab for psoriasis and psoriatic arthritis. Clin Exp Rheumatol 2002; 20(6 Suppl 28): S122-5.
9. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
10. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol 2002; 46: 886-91.
11. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627-32.
12. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98: 1315-24.
13. Kugathasan S, Levy MB, Saeian K, Vasilopoulos S, Kim JP, Prajapati D, et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol 2002; 97: 1408-14.
14. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
15. Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-8.
16. Sussman GL, Davis K, Kohler PF. Penicillin allergy: a practical approach to management. CMAJ 1986; 134: 1353-6.
17. Rubin RL, Nusinow SR, Johnson AD, Rubenson DS, Curd JG, Tan EM. Serologic changes during induction of lupus-like disease by procainamide. Am J Med 1986; 80: 999-1002.